Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Horst Sievert,
Discussant Report: The investigators made assumptions about thromboembolic complications of elective peripheral interventions based on the published results. They developed a concept to prevent these complications with abciximab (ReoPro) and conducted a randomized multicenter trial.
This trial failed its primary combined endpoint death, amputation, re-intervention or occlusion at 30 days. There was a significant reduction of intraprocedural peripheral embolism and a significant reduction in 6 months target vessel occlusion but also a five-fold increase of severe bleeding complications.
This trial was very well designed and carefully conducted. Although the primary endpoint failed, there was some improvement with ReoPro, which was not only statistically significant but also clinically relevant. However, bleeding complications are a major cause of morbidity and mortality of peripheral interventions. Therefore the observed increase in bleeding complications is not acceptable. It is unclear whether the bleeding complications could be reduced by modified access site management. According to these results, ReoPro seems not to be indicated in elective peripheral interventions. It may be that sub-group analyses (diabetes?) will give more insights.
Reopro and peripheral arterial intervention to improve clinical outcome in patients with peripheral arterial disease (RIO-Trial).